Adropin
An endogenous peptide hormone with apparent metabolic-regulatory effects — early academic biology with no advanced clinical program yet.
Investigational compounds — read carefully
This section covers peptides at the frontier of research. Most entries are preclinical, in early or mid-stage clinical trials, or theoretical. Evidence levels are explicitly marked on every entry.
Nothing on these pages constitutes medical advice, dosing recommendations, or instructions for use. Many of these compounds are not commercially available; some are not legal for human use. Decisions about treatment require a qualified clinician.
At a glance
A 76-amino-acid peptide hormone identified in 2008, encoded by the ENHO gene, with effects on glucose and lipid metabolism, endothelial function, and energy homeostasis. Circulating adropin is reduced in obesity and metabolic syndrome, suggesting a potential therapeutic axis through restoration or analog development.
- Class
- Endogenous peptide hormone
- Sponsor
- Multiple academic research programs
- Stage
- Preclinical
- Lead use cases
- Metabolic dysfunction, endothelial function, obesity
What it is
Adropin is a 76-amino-acid peptide hormone encoded by the ENHO (energy homeostasis associated) gene, originally identified by Andrew Butler's group in 2008. It is expressed in liver, brain, and other tissues and circulates as a hormone with apparent regulatory effects on glucose and lipid metabolism, endothelial function, and possibly energy expenditure.
Current research status
Adropin remains in preclinical and translational research without an advanced pharmaceutical development program. Multiple human observational studies have established that circulating adropin is reduced in obesity, metabolic syndrome, T2D, and several other dysmetabolic states — supporting the therapeutic-restoration hypothesis. Engineered adropin analogs and small-molecule pathway agonists are at early development stages.
Mechanistic rationale
Adropin's full mechanistic picture is still being assembled. Reported actions include modulation of hepatic lipid metabolism (reducing hepatic steatosis in animal models), improved glucose tolerance and insulin sensitivity, and direct effects on vascular endothelial function via pathways including eNOS activation. The receptor identity and signaling cascade are areas of active investigation; the GPR19 receptor has been proposed but the full pharmacology is not settled.
Available evidence
Discovery (Kumar et al., Cell Metab 2008) — Original characterization of adropin and its metabolic-regulatory effects in mouse models.[1]
Human observational studies — Multiple studies report reduced circulating adropin in obesity, T2D, NAFLD, and cardiovascular disease.[2]
Animal models of metabolic dysfunction — Adropin administration reduces hepatic steatosis, improves glucose tolerance, and improves endothelial function in obese rodent models.[3]
Why it's interesting
Adropin represents a distinct mechanistic axis from the dominant incretin/amylin classes in obesity pharmacology. If long-acting analogs or GPR19-pathway agonists can be engineered, the metabolic-restoration framing offers complementary therapeutic potential for patients who don't respond well to incretin therapy or who have specific NAFLD/endothelial-dysfunction phenotypes. The observational reduction of adropin in obesity is reproducible across multiple cohorts.
Limitations & risks
The mechanistic picture is incomplete — receptor identity, signaling pathways, and whether observational adropin reduction reflects causation or consequence remain open. Native adropin has a short plasma half-life. Translation from rodent metabolic models to human clinical effects has not yet been characterized. Pharmaceutical development is at an early stage.
Community discussion notes
Limited biohacker-community awareness given the early-stage development. Of considerable academic interest as an addition to the endogenous metabolic-regulatory peptide landscape alongside FGF21, GDF15, leptin, and the spexin/galanin axis.
The takeaway
Adropin is one of the more interesting endogenous metabolic peptides currently in preclinical academic research. The replicated observational reduction in obesity and metabolic dysfunction is supportive of a therapeutic-restoration hypothesis, but engineered analogs and clinical translation remain at early stages. Likely 5+ years from any clinical application; an interesting axis to watch for those following the broader endogenous-peptide-restoration approach to metabolic disease.
References
- Kumar KG, et al. Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism. Cell Metab. 2008;8(6):468-481. https://pubmed.ncbi.nlm.nih.gov/19041763/
- Butler AA, et al. Low circulating adropin concentrations with obesity and aging correlate with risk factors for metabolic disease and increase after gastric bypass surgery in humans. J Clin Endocrinol Metab. 2012;97(10):3783-3791. https://pubmed.ncbi.nlm.nih.gov/22872690/
- Gao S, et al. Therapeutic effects of adropin on glucose tolerance and substrate utilization in diet-induced obese mice with insulin resistance. Mol Metab. 2015;4(4):310-324. https://pubmed.ncbi.nlm.nih.gov/25830094/